247 related articles for article (PubMed ID: 26376374)
21. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group.
Santos PC; Soares RA; Nascimento RM; Machado-Coelho GL; Mill JG; Krieger JE; Pereira AC
BMC Med Genet; 2011 Oct; 12():136. PubMed ID: 21992719
[TBL] [Abstract][Full Text] [Related]
22. Researchers worry about myopathy risk for patients taking high-dose simvastatin.
Mitka M
JAMA; 2009 Jan; 301(3):261-2. PubMed ID: 19155447
[No Abstract] [Full Text] [Related]
23. SLCO1B1 Gene Polymorphisms (rs2306283 and rs4149056) and Statin-Induced Myopathy in Jordanian Diabetics.
Shahrure ZM; Irshaid YM; Mustafa KN; Abujbara MA; Al Shhab M; El-Khateeb MS; Ajlouni KM
Curr Rev Clin Exp Pharmacol; 2021; 16(3):281-288. PubMed ID: 32860365
[TBL] [Abstract][Full Text] [Related]
24. [Genetic marker of statin-induced rhabdomyolysis].
Chiba K; Morimoto K
Yakugaku Zasshi; 2011 Feb; 131(2):247-53. PubMed ID: 21297370
[TBL] [Abstract][Full Text] [Related]
25. Association between SLCO1B1 521 T＞C and 388 A＞G Polymorphisms and Statins Effectiveness: A Meta-Analysis.
Dai R; Feng J; Wang Y; Yang Y; Deng C; Tang X; Zhao Y; Zhou H; Zhang F
J Atheroscler Thromb; 2015 Aug; 22(8):796-815. PubMed ID: 25832498
[TBL] [Abstract][Full Text] [Related]
26. Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy.
Alghalyini B; El Shamieh S; Salami A; Visvikis Siest S; Fakhoury HM; Fakhoury R
Drug Metab Pers Ther; 2018 Mar; 33(1):41-47. PubMed ID: 29420305
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients.
Toms TE; Smith JP; Panoulas VF; Douglas KM; Saratzis AN; Kitas GD
Musculoskeletal Care; 2010 Mar; 8(1):2-9. PubMed ID: 19642078
[TBL] [Abstract][Full Text] [Related]
28. Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.
Carr DF; Francis B; Jorgensen AL; Zhang E; Chinoy H; Heckbert SR; Bis JC; Brody JA; Floyd JS; Psaty BM; Molokhia M; Lapeyre-Mestre M; Conforti A; Alfirevic A; van Staa T; Pirmohamed M
Clin Pharmacol Ther; 2019 Dec; 106(6):1353-1361. PubMed ID: 31220337
[TBL] [Abstract][Full Text] [Related]
29. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
Ramakumari N; Indumathi B; Katkam SK; Kutala VK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
[TBL] [Abstract][Full Text] [Related]
30. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.
Liu JE; Liu XY; Chen S; Zhang Y; Cai LY; Yang M; Lai WH; Ren B; Zhong SL
Eur J Clin Pharmacol; 2017 Nov; 73(11):1409-1416. PubMed ID: 28812116
[TBL] [Abstract][Full Text] [Related]
31. The genetics of statin-induced myopathy.
Ghatak A; Faheem O; Thompson PD
Atherosclerosis; 2010 Jun; 210(2):337-43. PubMed ID: 20042189
[TBL] [Abstract][Full Text] [Related]
32. Statin-induced myopathy SLCO1B1 521T > C is associated with prediabetes, high body mass index and normal lipid profile in Emirati population.
Saber-Ayad M; Manzoor S; El-Serafi A; Mahmoud I; Abusnana S; Sulaiman N
Diabetes Res Clin Pract; 2018 May; 139():272-277. PubMed ID: 29534995
[TBL] [Abstract][Full Text] [Related]
33. Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.
Vassy JL; Gaziano JM; Green RC; Ferguson RE; Advani S; Miller SJ; Chun S; Hage AK; Seo SJ; Majahalme N; MacMullen L; Zimolzak AJ; Brunette CA
JAMA Netw Open; 2020 Dec; 3(12):e2027092. PubMed ID: 33270123
[TBL] [Abstract][Full Text] [Related]
34. Simvastatin-induced myopathy with concomitant use of cyclosporine: case report.
Yang WH; Zeng ZS; Ren XW; Li YP; Shang WJ; Feng GW; Zhang LR
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):772-7. PubMed ID: 22122820
[TBL] [Abstract][Full Text] [Related]
35. Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.
Bakar NS; Neely D; Avery P; Brown C; Daly AK; Kamali F
Clin Pharmacol Ther; 2018 Jul; 104(1):178-187. PubMed ID: 28940218
[TBL] [Abstract][Full Text] [Related]
36. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis.
Xiang Q; Zhang XD; Mu GY; Wang Z; Liu ZY; Xie QF; Hu K; Zhang Z; Ma LY; Jiang J; Cui YM
Eur J Clin Pharmacol; 2021 Apr; 77(4):569-581. PubMed ID: 33150478
[TBL] [Abstract][Full Text] [Related]
37. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
[TBL] [Abstract][Full Text] [Related]
38. A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance.
Bigossi M; Maroteau C; Dawed AY; Taylor A; Srinivasan S; Melhem AL; Pearson ER; Pola R; Palmer CNA; Siddiqui MK
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):536-545. PubMed ID: 37253618
[TBL] [Abstract][Full Text] [Related]
39. Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report.
Kiage J; Venkatanarayan A; Roth M; Elam M
J Clin Lipidol; 2022; 16(1):23-27. PubMed ID: 34887219
[TBL] [Abstract][Full Text] [Related]
40. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH
Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
